Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirvetuximab soravtansine + bevacizumab + carboplatin
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
The combination **mirvetuximab soravtansine + bevacizumab + carboplatin** is under clinical investigation as a regimen for treating recurrent, platinum-sensitive or platinum-resistant epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Mirvetuximab soravtansine is an antibody-drug conjugate that targets folate receptor alpha (FRα) via a humanized monoclonal antibody and delivers the cytotoxic maytansinoid DM4, a tubulin inhibitor. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. Carboplatin is a platinum compound that forms DNA crosslinks, disrupting DNA repair and leading to apoptosis. This triplet is used in regimens where folate receptor alpha expression is detected in tumors. The combination is highly active in recurrent, platinum-sensitive cases, showing high objective response rates and durable progression-free survival, with the main dose-limiting toxicity being thrombocytopenia[3][5].
- Other names
- mirvetuximab soravtansine + bevacizumab + carboplatinMIRV + bevacizumab + carboplatinMIRV + carboplatin + bevacizumabRegimen E
02
Targets
Beyond the preview
Go deeper on mirvetuximab soravtansine + bevacizumab + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirvetuximab soravtansine + bevacizumab + carboplatin.